PD-1 Blockade in Renal Cell Carcinoma
Setting Name Study design Primary endpoints Estimated end of study First line CAG209-214 NCT02231749 Nivolumab + ipilimumab vs Sutent Phase III PFS and OS June 2019 First line IMmotion 151…
Setting Name Study design Primary endpoints Estimated end of study First line CAG209-214 NCT02231749 Nivolumab + ipilimumab vs Sutent Phase III PFS and OS June 2019 First line IMmotion 151…
© Springer International Publishing AG 2018Laurence Zitvogel and Guido Kroemer (eds.)Oncoimmunologyhttps://doi.org/10.1007/978-3-319-62431-0_1 1. Principles of Oncoimmunology Laurence Zitvogel1, 2, 3, 4 and Guido Kroemer1, 5, 6, 7, 8, 9, 10 (1) Gustave Roussy, Cancer Campus, Villejuif, France (2)…
© Springer International Publishing AG 2018Laurence Zitvogel and Guido Kroemer (eds.)Oncoimmunologyhttps://doi.org/10.1007/978-3-319-62431-0_3 3. CD8+ T Cells in Immunotherapy, Radiotherapy, and Chemotherapy Weimin Wang1, 2, Michael Green1, 3, J. Rebecca Liu2, Theodore S. Lawrence3 and Weiping Zou1, 4 (1) Department of Surgery, University…